South Dakota Investment Council - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 213 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.87 and the average weighting 0.3%.

Quarter-by-quarter ownership
South Dakota Investment Council ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2021$159,000
-6.5%
6,8900.0%0.00%0.0%
Q4 2020$170,000
-40.6%
6,8900.0%0.00%
-50.0%
Q3 2020$286,000
-13.3%
6,8900.0%0.01%
-25.0%
Q2 2020$330,000
-24.0%
6,8900.0%0.01%
-33.3%
Q1 2020$434,000
-49.2%
6,8900.0%0.01%
-33.3%
Q4 2019$854,000
+38.4%
6,890
-25.9%
0.02%
+50.0%
Q3 2019$617,000
-16.6%
9,3000.0%0.01%
-20.0%
Q2 2019$740,000
-65.0%
9,300
-50.8%
0.02%
-66.7%
Q1 2019$2,114,000
-59.3%
18,900
-57.9%
0.04%
-26.2%
Q4 2018$5,190,000
+58.0%
44,900
+72.7%
0.06%
-14.1%
Q3 2018$3,285,000
+36.9%
26,000
-9.1%
0.07%
+36.5%
Q2 2018$2,400,000
-14.4%
28,600
-37.3%
0.05%
-18.8%
Q1 2018$2,805,000
+5.3%
45,6000.0%0.06%
+8.5%
Q4 2017$2,664,000
+7.7%
45,600
+7.0%
0.06%
+18.0%
Q3 2017$2,473,000
-52.1%
42,6000.0%0.05%
-54.1%
Q2 2017$5,158,000
+7.1%
42,6000.0%0.11%
+11.2%
Q1 2017$4,818,000
-0.1%
42,600
-4.1%
0.10%
-3.9%
Q4 2016$4,824,000
-34.0%
44,4000.0%0.10%
-32.5%
Q3 2016$7,308,000
+15.4%
44,4000.0%0.15%
+8.6%
Q2 2016$6,335,000
+2.7%
44,400
-7.5%
0.14%
+3.0%
Q1 2016$6,167,000
+14.1%
48,000
+32.6%
0.14%
+14.4%
Q4 2015$5,406,000
-3.9%
36,200
+6.8%
0.12%
-8.5%
Q3 2015$5,623,000
-27.7%
33,900
+5.3%
0.13%
-17.3%
Q2 2015$7,772,000
-18.2%
32,200
-4.5%
0.16%
-14.3%
Q1 2015$9,504,000
+54.2%
33,700
-14.7%
0.18%
+50.4%
Q4 2014$6,162,00039,5000.12%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2019
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 234,375$23,623,00022.67%
Boxer Capital, LLC 600,000$60,474,0007.47%
DLD Asset Management, LP 834,600$84,136,0005.77%
GREAT POINT PARTNERS LLC 200,000$20,158,0002.55%
BB BIOTECH AG 575,719$58,027,0001.86%
Elk Creek Partners, LLC 207,657$20,930,0001.74%
ALTRINSIC GLOBAL ADVISORS LLC 277,944$28,014,0001.34%
Sarissa Capital Management LP 54,000$5,442,0001.21%
QCM Cayman, Ltd. 2,181$220,0000.90%
Opus Point Partners Management, LLC 3,534$356,0000.78%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders